Loading…
5 companies · GEL, thousands · columns ordered by revenue
Only 3 of 5 peers filed FY2024. Switch to FY2023 (4 of 5).
| Line item | Med Treideri | Pulparmi | NS Georgia | Maksparma | Anshen Pharma |
|---|---|---|---|---|---|
| Total Revenue | 1,732 | 1,729 | 1,670 | — | — |
| Total COGS | -993 | -1,337 | -1,108 | — | — |
| Gross Profit | 739 | 393 | 563 | — | — |
| Gross Margin | 42.7% | 22.7% | 33.7% | — | — |
| Total Operating Expenses | -716 | -253 | -370 | — | — |
| EBITDA | 23 | 140 | 193 | — | — |
| EBITDA Margin | 1.3% | 8.1% | 11.5% | — | — |
| Total D&A | -3 | -3 | -27 | — | — |
| EBIT / Operating Income | 20 | 137 | 166 | — | — |
| Total Interest Expense | -40 | — | — | — | — |
| Profit Before Tax | -20 | 137 | 158 | — | — |
| Total Income Tax | 0 | 0 | -19 | — | — |
| Net Profit / (Loss) | -20 | 137 | 139 | — | — |
| Net Margin | -1.2% | 7.9% | 8.3% | — | — |
| Other Comprehensive Income | — | -12 | — | — | — |
| Total Comprehensive Income | — | 125 | — | — | — |
| Total Other Income | — | — | -8 | — | — |
Not every picked company reports every selected year — FY2024: no filing for Anshen Pharma and Maksparma. Those cells are left blank (no filing), not zero.
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| NS Georgia | Pharma | 11.5% | 44th pct | 110 |
| Pulparmi | Pharma | 8.1% | 35th pct | 110 |
| Med Treideri | Pharma | 1.3% | 17th pct | 110 |
| Maksparma | Pharma | — | no FY data | 110 |
| Anshen Pharma | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.